- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01733472
General or Regional Anesthesia for Hip Surgery
General Versus Intrathecal Anaesthesia for Patients Undergoing Elective Total Hip Arthroplasty
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
A randomized controlled trial (RCT) with a follow up time of 48 hrs. Patients scheduled for primary Total Hip Arthroplasty. A total of 120 patients randomly assigned to one of the two alternatives (general anaesthesia (GA) or regional anaesthesia (RA)).
General anaesthesia compared to intrathecal anaesthesia will give shorter length of hospital stay (LOS) for patients undergoing total hip arthroplasty (THA).
Primary endpoint:
LOS.
Secondary endpoints:
Postoperative pain? Postoperative orthostatic function (dizziness) Time until the patient meets the discharge criteria from PACU How many patients will need at least one urinary bladder catheterisation
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Hässleholm, Sverige, 28125
- Dept Orthopedic Surgey, Hässleholm Hospital, PO Box 351,
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria: patients with osteoarthritis scheduled for surgery
- patients that will require THA
- patients over 45 yrs and under 85 yrs.
- patients that understand the given information and are willing to participate in this study
- patients who have signed the informed consent document.
- patients belonging to ASA class I-III.
Exclusion Criteria:
- prior surgery to the same hip
- patients with a history of stroke, neurological or psychiatric disease that potentially could affect the perception of pain
- obesity (BMI > 35)
- active or suspected infection
- patients taking opioids or steroids
- patients suffering from rheumatoid arthritis or an immunological depression
- patients who are allergic to any of the drugs being used in this study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: RA-arm
RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
|
Intrathecal (i.e.
spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
Andre navn:
|
|
Eksperimentell: GA-arm, remifentanil
GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
|
Remifentanil and propofol will be delivered intravenously via TCI pumps according to the "Marsh" and "Minto" algorithm
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Length of Hospital Stay
Tidsramme: Up to 4 days after surgery
|
Time from the end of surgery until the patients meets the discharge criteria will be evaluated.
Discharge criteria: able to get in and out of bed, Able to get dressed.
Able to sit down in a chair and get up again.
Able to walk 50 meters wit/without crutches.
Able to flex knee 70 degrees.
Able to walk stairs.
Pain manageable with oral analgesics.
Acceptance to be discharged
|
Up to 4 days after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Post Operative Pain
Tidsramme: from end of surgey until 48 hrs later
|
Pain will be monitored using a Visual Analogue Scale.
Pain will be monitored with the patient in four different positions.
VAS 100 mm used for assessment of pain (0 = no pain, 100 = worst imaginable pain).
At each time and position the median VAS-pain score was reported (generally the distribution of pain scores are not normally distributed and hence median value was used)
|
from end of surgey until 48 hrs later
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time Hrs Until the Patient Meets the Discharge Criteria From PACU
Tidsramme: 12 hrs
|
Hours until the patient meets the discharge criteria from PACU will be monitored every 15 min from teh time the patient arrives to PACU until he/she meets the discharge criteria
|
12 hrs
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Andreas Harsten, M.D., Region Skane
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2008 Feb;100(2):154-64. doi: 10.1093/bja/aem373.
- Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997 Jan;86(1):24-33. doi: 10.1097/00000542-199701000-00005.
- Marsh BJ, Morton NS, White M, Kenny GN. A computer controlled infusion of propofol for induction and maintenance of anaesthesia in children. Can J Anaesth. 1990 May;37(4 Pt 2):S97. No abstract available.
- Harsten A, Kehlet H, Ljung P, Toksvig-Larsen S. Total intravenous general anaesthesia vs. spinal anaesthesia for total hip arthroplasty. Acta Anaesthesiol Scand. 2015 Apr;59(4):542-3. doi: 10.1111/aas.12495. Epub 2015 Mar 3. No abstract available.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Leddsykdommer
- Muskel- og skjelettsykdommer
- Revmatiske sykdommer
- Leddgikt
- Artrose
- Fysiologiske effekter av legemidler
- Sentralnervesystemdepressiva
- Agenter fra det perifere nervesystemet
- Analgetika
- Sensoriske systemagenter
- Anestesimidler, intravenøst
- Anestesimidler, general
- Bedøvelsesmidler
- Analgetika, opioid
- Narkotika
- Hypnotika og beroligende midler
- Remifentanil
- Propofol
Andre studie-ID-numre
- Hip-CPH-2013
- Hässleholm2013 (Annen identifikator: Region Skåne)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .